Abbott Completes $21 Billion Acquisition of Exact Sciences, Becomes Leader in Cancer Diagnostics
ABT is trading near its 52-week low of $105.27 (1.3% above the low) on elevated volume (7.5× avg).
Summary
Abbott Laboratories has completed its $21 billion acquisition of Exact Sciences, significantly expanding its footprint and leadership in the high-growth cancer diagnostics market.
Key Events · M&A and Partnerships · ABT
-
Acquisition Completed
Abbott Laboratories finalized its acquisition of Exact Sciences Corporation on March 23, 2026, for $105.00 per share in cash, following the initial agreement in November 2025.
-
Strategic Market Expansion
This acquisition establishes Abbott as a leader in the fast-growing $60 billion U.S. cancer screening and precision oncology diagnostics segments, adding a new growth vertical.
-
Enhanced Product Portfolio
Abbott gains a comprehensive suite of cancer detection and treatment products, including Cologuard, Oncotype DX, Oncodetect, and Cancerguard, along with a robust pipeline.
Analysis · ABT · Life Sciences
Abbott Laboratories has completed its significant acquisition of Exact Sciences Corporation, a strategic move that positions the company as a leader in the rapidly expanding cancer screening and diagnostics market. This $21 billion transaction, initially agreed upon in November 2025 and highlighted in Abbott's recent 10-K, is expected to add a new growth vertical and enhance Abbott's presence in the $60 billion U.S. cancer diagnostics segment. The integration of Exact Sciences' portfolio, including key products like Cologuard and Oncotype DX, provides Abbott with a comprehensive suite of offerings for early cancer detection and personalized treatments. This strategic expansion is a long-term growth driver for Abbott, occurring while the company's stock is trading near its 52-week low, suggesting potential for future upside as the market fully digests the benefits of this acquisition.
At the time of this filing, ABT was trading at $106.67 on NYSE in the Life Sciences sector, with a market capitalization of approximately $183.3B. The 52-week trading range was $105.27 to $139.06. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.